Skip to content

Study · Observational study · n = 190 · 2021

4 results

High baseline FGF21 levels are associated with poor glucose-lowering efficacy of exenatide in patients with type 2 diabetes.

Yang K, Wang H, Wei R, Xiao W, Tian Q, Wang C, Yang J, Hong T

Acta diabetologica15 Jan 2021Cited by 9 (Europe PMC)

PMID33452595 (opens in a new tab)DOI10.1007/s00592-020-01660-z (opens in a new tab)PepBankPUB-33452595
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In patients with type 2 diabetes receiving exenatide, baseline FGF21 correlated with HbA1c decline.

    In plain wordsIn patients taking exenatide, baseline FGF21 was linked to HbA1c decline.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableFGF21 association with HbA1c response
    Study

    n = 190

    Analysis
    Exploratory
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Measurements

    Correlation r, baseline FGF21 vs HbA1c decline
    0.193 r
    all participants

    Source sentences

    Summary
    After 16 weeks of treatment with exenatide, a decline in the HbA1c levels from baseline was associated with higher baseline FGF21 levels among all participants (r = 0.193, P = 0.008)
    2 context sentences
    Summary · context
    The exploratory analysis of a multi-center trial included 190 patients with type 2 diabetes inadequately controlled by monotherapy or combination therapy of metformin and insulin secretagogues.
    Summary · context
    All participants received exenatide twice daily as an add-on therapy for 16 weeks.
  2. 02HumanObservational studyEfficacy outcome

    In patients receiving background metformin monotherapy and exenatide, baseline FGF21 correlated with HbA1c decline.

    In plain wordsIn patients taking metformin and exenatide, baseline FGF21 was linked to HbA1c decline.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableFGF21 association with HbA1c response on metformin
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Measurements

    Correlation r, baseline FGF21 vs HbA1c decline
    0.231 r
    background metformin monotherapy subgroup

    Source sentences

    Summary
    and in subgroup of the participants receiving background metformin monotherapy (r = 0.231, P = 0.034).
    2 context sentences
    Summary · context
    The exploratory analysis of a multi-center trial included 190 patients with type 2 diabetes inadequately controlled by monotherapy or combination therapy of metformin and insulin secretagogues.
    Summary · context
    All participants received exenatide twice daily as an add-on therapy for 16 weeks.
  3. 03HumanObservational studyEfficacy outcome

    In patients receiving exenatide, the highest baseline FGF21 quartile had a weaker adjusted HbA1c decline than the lowest quartile.

    In plain wordsIn patients taking exenatide, the highest FGF21 quartile was linked to less HbA1c improvement than the lowest quartile.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHbA1c response by FGF21 quartile
    Study

    n: not reported in source

    Comparator
    Lowest FGF21 quartile
    Analysis
    Exploratory
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Measurements

    Adjusted beta, highest vs lowest FGF21 quartile, HbA1c decline
    −0.16 β
    all participants

    Source sentences

    Summary
    Compared with patients in the lowest FGF21 quartile, patients in the highest FGF21 quartile showed a significantly weakened decline in HbA1c levels from baseline among all participants (β = - 0.16 [95% Cl - 0.31 to - 0.01], P < 0.05)
    3 context sentences
    Summary · context
    after adjusting for the confounding factors, including age, sex, and baseline HbA1c levels.
    Summary · context
    The exploratory analysis of a multi-center trial included 190 patients with type 2 diabetes inadequately controlled by monotherapy or combination therapy of metformin and insulin secretagogues.
    Summary · context
    All participants received exenatide twice daily as an add-on therapy for 16 weeks.
  4. 04HumanObservational studyEfficacy outcome

    In patients receiving metformin and exenatide, the highest FGF21 quartile had a weaker adjusted HbA1c decline than the lowest quartile.

    In plain wordsWith metformin and exenatide, the highest FGF21 quartile was linked to less HbA1c improvement than the lowest quartile.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHbA1c response by FGF21 quartile on metformin
    Study

    n: not reported in source

    Comparator
    Lowest FGF21 quartile
    Analysis
    Exploratory
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Measurements

    Adjusted beta, highest vs lowest FGF21 quartile, HbA1c decline
    −0.23 β
    background metformin monotherapy subgroup

    Source sentences

    Summary
    and in subgroup of the participants receiving background metformin monotherapy (β = - 0.23 [95% Cl - 0.43 to - 0.03], P < 0.05)
    3 context sentences
    Summary · context
    Compared with patients in the lowest FGF21 quartile, patients in the highest FGF21 quartile showed a significantly weakened decline in HbA1c levels from baseline among all participants (β = - 0.16 [95% Cl - 0.31 to - 0.01], P < 0.05)
    Summary · context
    The exploratory analysis of a multi-center trial included 190 patients with type 2 diabetes inadequately controlled by monotherapy or combination therapy of metformin and insulin secretagogues.
    Summary · context
    All participants received exenatide twice daily as an add-on therapy for 16 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.